- Market Radar
- /
- BTAI
Sagehood
Financial Analyst
PREMIUM
Technical Trader
PREMIUM
Valuation Projection
PREMIUM
Social Media Buzz
PREMIUM
News Agent
PREMIUM
Macro Economist
PREMIUM
About BTAI
7/28/2025
Comprehensive Analysis
Financial Health
- Balance Sheet & Liquidity: BioXcel Therapeutics (BTAI) exhibits severe financial stress, with negative equity (-$90.17M as of Q1 2025) and total liabilities exceeding assets. The current ratio (1.48) and quick ratio (1.27) suggest limited short-term liquidity, while long-term debt ($100M) and negative free cash flow (-$72M TTM) highlight solvency risks.
Free Insights for Smarter Investing
Get 5 daily AI-powered insights on your favorite stocks-absolutely free.
Free Account
- View 5 tickers daily
- Create and manage Watchlists
- Import portfolios (no personalized insights)
- Chat with the general Sagehood AI Agent
- Market Radar: Preview access only
Premium Membership
- Unlimited AI-generated insights across all sections
- Market Overview
- Market Radar (AI-driven investment opportunities)
- Access to all Sagehood AI agents, including domain-specific experts
- Personalized insights and actionable recommendations for smarter investing